Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.

@article{Algiraigri2017HydroxyureaFN,
  title={Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.},
  author={Ali H Algiraigri and Nicola A. M. Wright and Elizabeth Oddone Paolucci and Aliya Kassam},
  journal={Hematology/oncology and stem cell therapy},
  year={2017},
  volume={10 3},
  pages={
          116-125
        }
}
OBJECTIVE/BACKGROUND Nontransfusion-dependent β-thalassemia (NTDβT) syndromes consist of β-thalassemia intermedia and moderate hemoglobin E/β thalassemias. They are characterized by varying degrees of chronic anemia and a wide spectrum of complications due to ineffective erythropoiesis and iron overload from chronic transfusions. Hydroxyurea (HU), an oral chemotherapeutic drug, is anticipated to decrease disease severity. METHODS We performed a meta-analysis to evaluate the clinical efficacy… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Hydroxyurea-induced hematological response in transfusion- Please cite this article in press as: Algiraigri AH et al., Hydroxyurea fo meta-analysis

MA Ehsani, AA Hedayati-Asl, A Bagheri, S Zeinali, A. Rashidi
  • Hematol Oncol Stem Cell Ther
  • 2017
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…